Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor’s Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer
“The initiation of this study is another important milestone for our Hsp90 inhibitor program,” said David Grayzel, M.D., vice president, clinical development and medical affairs, Infinity. “We are encouraged by the evidence of biological activity we saw in the Phase 1 portion of the study and are eager to further evaluate IPI-504 in Phase 2. Non-small cell lung cancer is an aggressive disease and we are grateful to the patients, their families, and the outstanding caregivers collaborating with us in order to develop potential new treatment options.”
This entry was posted on Friday, December 21st, 2007 at 6:31 pm and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.